Articles tagged with Liver Cancer
A University of Colorado study found that Hispanic white and non-Hispanic black young adults are more likely to die from cancer than their white counterparts, with mortality risks ranging from 1.36 to 1.77 times higher.
Research found that high levels of the protein p62 are strongly associated with cancer recurrence and reduced patient survival in human liver samples. In mice, p62 was required for liver cancer to form. The study suggests p62 could be used as a prognostic marker and potential therapeutic target for liver cancer.
A recent study published in JAMA Internal Medicine found that higher levels of leisure-time physical activity were associated with lower risks for 13 types of cancers. The analysis included 1.4 million participants and 186,932 cancers identified during a median of 11 years of follow-up.
The Medical University of South Carolina's Hollings Cancer Center is awarded a grant to explore lipid signaling mechanisms in cancer cell proliferation, resistance to apoptosis, and metastasis. The project aims to develop new therapeutic strategies for solid tumors, including liver, prostate, and urinary cancers.
Dr. Hao Zhu has been awarded a $750,000 Stand Up To Cancer grant to investigate the relationship between injury, regeneration, and cancer. His research aims to understand the mechanisms shared by cancer and organ regeneration, with potential therapeutic targets in tissue repair and cancer prevention.
A study at the University of Texas M. D. Anderson Cancer Center found that normal liver cells metabolize dietary fructose differently than cancerous cells, revealing a potential diagnostic marker for liver cancer. The researchers discovered a gene called KHK that is expressed differently in healthy and tumor tissues.
A recent mouse study found that antioxidants in certain antidiabetic medications can accelerate the spread of colon and liver cancer. The findings suggest that these medications, which are commonly used to treat diabetes, may not be safe for diabetic patients with cancer.
CRI researchers found that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. The study showed that mice without the gene had healthier livers, improved liver function, and faster healing of damaged tissues.
A new study suggests that consuming broccoli may protect against liver cancer and aid in countering the development of fatty liver disease. The researchers found that adding broccoli to a Westernized diet reduced the formation of cancer nodules in the liver and improved liver health.
Researchers at UT Southwestern Medical Center developed a nanoparticle therapy that combines LDL and fish oil to preferentially kill primary liver cancer cells. The approach shows significant anti-cancer activity, with over 80% of tumor cells dying, and holds promise for potentially treating other cancers.
A new report estimates 4.3 million new cancer cases and 2.8 million deaths in China in 2015, with lung cancer the leading cause of cancer death. The study highlights the need to reduce risk factors and improve clinical care delivery to prevent avoidable cancer deaths.
Researchers create synthetic nanoparticles that can deliver miRNA-based therapies to late-stage liver cancer, inhibiting tumor growth and extending survival. The breakthrough addresses a major challenge in treating aggressive liver cancer, offering hope for patients with limited treatment options.
Cancer rates vary significantly among Asian American/Native Hawaiian/Pacific Islander populations, with Samoan men having the highest lung cancer rates and Laotian men having the highest liver cancer rates. Breast cancer mortality rates have decreased among AANHPI women combined, while liver cancer death rates declined among AANHPI males.
A new study published in JAMA Oncology found that solid-organ transplant recipients have a significantly higher cancer death rate than the general population. The research, which analyzed data from over 11,000 transplanted patients between 1991 and 2010, revealed that SOTRs were at increased risk of cancer death regardless of age, sex,...
Scientists at USC have discovered the Achilles heel of hepatocellular carcinoma, a leading cause of cancer deaths worldwide. Researchers identified the carcinogenic pathway of stem cell marker NANOG, which promotes cancer spread by rewiring metabolism in mitochondria.
Researchers have identified saffron-based 'crocin' as a potential therapeutic agent against liver cancer, leveraging preclinical studies and network analyses. Crocin's mechanism involves regulating NF-kB, a key hub in liver cancer development, suggesting it as a promising target for early lesion prevention.
Researchers have developed a novel method to reposition an FDA-approved anti-cancer compound for targeting liver cancer tumors. The 'triple attack' technique uses nanobubbles filled with the drug to specifically target cancer cells, minimizing harm to healthy tissue.
Researchers at Hiroshima University have discovered that fragments of cancer DNA circulating in the bloodstream can predict the recurrence and spread of liver cancer. This non-invasive method, known as circulating tumor DNA (ctDNA), provides valuable clinical information about the patient's disease progression.
Researchers developed a CRISPR/Cas9 approach to study and model cancer development in mice, uncovering cancer-causing roles and combinations of genes. The method enabled the identification of genes influencing liver and bile duct cancer development.
A cancer-causing parasitic worm has been discovered to drive wound healing and blood vessel growth, which could lead to accelerated recovery from chronic wounds such as diabetic ulcers. The growth factor secreted by the parasite also increases the risk of developing liver cancer over time.
Researchers at DTU Systems Biology have developed a new diagnostic technology, TumorTracer, which identifies the source of cancer with 85% certainty. The method uses advanced self-learning computer algorithms to analyze DNA mutations in cancer tissue samples.
According to a comprehensive report by the American Cancer Society, cancer is the second leading cause of death overall in the US, but it remains the leading cause of death among US Hispanics. Lung cancer is the primary concern, particularly for Hispanic men, who are more likely to die from this disease.
Men in China face increasing tobacco-related cancer risks due to high cigarette smoking rates among teenagers and continued use in adulthood. The country now produces and consumes nearly 40% of the world's cigarettes, primarily driven by men's smoking habits.
Researchers found that MACC1 expression is a key indicator of survival and recurrence risk in Klatskin carcinoma patients. Patients with low MACC1 levels have a good chance of benefiting from surgery, while those with high levels are at a higher risk of cancer recurrence.
Researchers identified a new virus, AAV2, associated with rare liver cancer cases without cirrhosis or known risk factors. The virus targets genes involved in cell proliferation, leading to excessive expression and potentially favoring tumor development.
A University of Hawai'i Cancer Center researcher has received a $2.70 million grant to study how gut bacteria can damage the liver and promote liver cancer. The study aims to design new approaches to preventing liver cancer by regulating bile acid metabolism.
A new study published in Journal of Hepatology found that women with intrahepatic cholestasis of pregnancy (ICP) are at a higher risk of hepatobiliary cancer and immune-mediated diseases later in life. ICP affects nearly 0.4-1.5% of pregnancies and is characterized by itching, elevated serum bile acids, and/or liver enzymes.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a new way to improve liver cancer treatment by blocking the activity of the lymphotoxin-beta receptor. The approach, which combines drugs currently in clinical trials with those targeting oncogene signals, may lead to improved patient outcomes.
A large population-based study found that women with intrahepatic cholestasis of pregnancy (ICP) have a higher risk of hepatobiliary cancer, immune-mediated diseases, and cardiovascular disease compared to those without the condition. ICP is characterized by pruritus, elevated serum bile acids, and liver enzymes in late pregnancy.
New cancer cases are increasing globally, with significant rises in prostate and breast cancer since 1990. However, death rates from cancer are falling in many countries due to prevention and treatment progress.
Exposure to aflatoxin, a liver carcinogen, is associated with an increased risk of gallbladder cancer in a small Chilean study. The study found higher levels of aflatoxin-albumin adducts in patients with gallbladder cancer compared to controls.
Patients with liver cancer can be cured with a liver transplant using organs from donors who died of cardiac death, according to the largest study of its kind. The study found no difference in liver cancer recurrence between livers donated after cardiac death and those obtained from brain-dead donors.
A new class of protein-based contrast agents (PRCAs) has been developed to detect liver cancer at an early stage, providing robust results. The agent, ProCA32, allows for imaging of liver tumors measuring less than 0.25 millimeters with improved sensitivity and accuracy compared to existing methods.
Researchers discovered that cancer rates among hepatitis C patients are significantly higher than those without the virus. The study found a 2.5 times higher rate of all cancers and almost twice as high when liver cancer is excluded.
Researchers have discovered a damaged DNA lesion that may serve as an early biomarker for liver cancer. Polyphenon E, a green tea extract, also shows promise in suppressing the lesion and preventing tumor development.
Researchers have unraveled the relationships between microRNA miR-22, bile acids, and Cyclin A2 in liver and colon cancer. The study found that miR-22 reduces Cyclin A2 expression levels, potentially leading to new cancer therapies.
A new study published in the Journal of the American College of Surgeons found that liver-sparing operations, which remove less than a lobe of the liver, are linked to lower mortality and complication rates. This approach is associated with quicker recovery times and fewer complications compared to traditional major hepatectomies.
A new UK-based study reveals that statin users have a lower risk of developing liver cancer compared to non-users. The study found the association was strongest among current users and those with pre-existing conditions like diabetes or liver disease.
Scientists from RIKEN have found that chronic hepatitis infection and inflammation can lead to similar genetic mutations in liver tumors, potentially paving the way for targeted therapies. The study identified changes in mutations associated with aggressive biliary-type liver cancers and discovered new targets for future treatments.
Researchers have identified a critical safety parameter related to AAV gene therapy, which can increase liver cancer risk. They found that modifying the vector to avoid targeting specific genes reduces cancer incidence, paving the way for safer gene therapies.
Researchers from Ruhr-University Bochum found that terpenes in citrus scents can inhibit liver cancer cell growth. The study discovered the signalling pathway used by (-)-citronellal and citronellol, two terpenes with anti-cancer properties.
A novel nomogram was developed by UCLA researchers to accurately calculate the risk of disease recurrence in liver cancer patients after a liver transplant. The tool uses pre-transplant radiologic information, blood biomarkers, and pathological characteristics to predict recurrence rates.
Researchers have found a new potential target for liver cancer treatment in the protein TREM-1, which accelerates chronic inflammation. Studies suggest that blocking TREM-1 can block the conversion of healthy cells to cancerous ones and even stop progression of existing cancer.
A 30-year study found that neonatal HBV vaccination significantly reduced the risk of primary liver cancer and other liver diseases in young adults. The study's results show that vaccination led to a 84% reduction in liver cancer incidence, highlighting the importance of early intervention.
A new imaging system has shown potential to reduce radiation exposure for patients undergoing intra-arterial therapy (IAT) for liver cancer, with a reduction of up to 80%, compared to standard X-ray platforms. The AlluraClarity platform uses real-time image processing algorithms to achieve high-quality images at lower radiation power.
CPRIT awards UTSW faculty $22.5 million for groundbreaking research into leukemia, liver cancer, and anti-cancer immunotherapy, aiming to drive innovative therapies and better care for cancer patients. The grants will support investigations targeting promising new discoveries in cancer and commercial development.
Researchers will investigate how the Western diet increases the risk of developing liver and gastrointestinal cancers. They also aim to determine if specific bifidobacteria species can mitigate the negative effects of a high-fat, high-sugar diet.
Researchers at VCU Massey Cancer Center have identified a genetic driver of inflammation that can be used to prevent and treat liver cancer. The study found that blocking the expression of AEG-1 halts the development and progression of liver cancer by regulating inflammation.
A meta-analysis of 16 studies and 891,426 participants found that prediabetes increases the risk of cancer by 15%. The risk was higher for certain types of cancer, including stomach/colorectum, liver, pancreas, breast, and endometrium.
CRI scientists have identified a gene that contributes to the development of several childhood cancers, including neuroblastoma and hepatoblastoma. The study found that overproduction of Lin28b specifically causes hepatoblastoma, while blocking it impairs cancer growth.
Researchers predict that effective new drugs and widespread screening will reduce hepatitis C cases, prevent liver cancer and deaths. By 2036, the disease is expected to affect only one in 1,500 people in the US.
A study found that genetic mutations in liver cells drive tumor formation in iCCA, with mutant proteins impairing liver cell development and increasing the risk of metastasis. Researchers discovered a potential treatment option by targeting IDH1/2 mutations, opening a new line of investigation for biomarkers and life-saving decisions.
Two studies published in Gastroenterology found that antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection. Younger patients with minimal liver damage and those treated with nucleos(t)ide analogues showed a significant reduction in liver cancer risk.
The American College of Physicians recommends assessing a woman's health history for unique events that increase her risk of stroke later in life. For chronic hepatitis C patients, routine screening for liver cancer may not lead to greater survival.
Scientists have developed a liver cancer vaccine that is effective in preventing the disease in mice, with the goal of improving patient survival rates. The vaccine targets a specific protein expressed by most liver cancer cells, allowing the immune system to recognize and attack them.
A review of 47 studies involving over 15,000 patients found that liver cancer screening using ultrasound scans and blood tests significantly improved three-year survival rates for people with cirrhosis. Cirrhosis patients who received screening were more likely to receive curative treatment rather than palliative care.
Deaths from viral hepatitis have surpassed HIV/AIDS as a preventable cause of death in Australia, with an estimated 1,500 liver cancer deaths per year. Chronic viral hepatitis can lead to cirrhosis or liver cancer if left untreated, but access to effective care and treatment can reduce these risks.
Researchers have discovered an immunotherapeutic approach to treating liver cancer, utilizing isolated T-cell receptors that can recognize and eliminate liver cancer cells. This new treatment option holds promise for patients with limited treatment options, including those with advanced stage HCC.
A University of Colorado Cancer Center study identifies AGL as a key driver of bladder cancer growth, linked to hereditary liver disease glycogen storage disease 3. Low AGL levels correlate with poorer prognosis and increased tumor proliferation.
A new study found that antioxidants may increase DNA damage from omega-6 fatty acids, but reduce formation of another type of damage. Green tea polyphenol and alpha-lipoic acid showed mixed effects on these damages.